CureTalks@Penn Research Interviews

Teclistamab is a bispecific IgG4 antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. According to the investigators, the current study is — to their knowledge — the first report of a T-cell — redirecting bispecific antibody for the treatment of patients with cancer.

Progress in antiretroviral therapy has considerably reduced mortality and notably improved the quality of life of individuals infected with HIV. However, drug resistance, treatment-associated toxicity, adherence to medication, and the need for lifelong therapy have remained major challenges. While the development of an HIV vaccine has remained elusive, considerable progress in developing innovative cell and gene therapies to treat HIV infection has been made.

CureTalks panel talks to Dr. Edward A. Stadtmauer about CRISPR-Cas9 gene editing system, scope of the tool in cancer treatment and management.

We are discussing the many perspectives related to gun violence and its impact on healthcare with an esteemed panel of experts from the University of Pennsylvania.

We sit down with Dr. Drew Weissman, who with his former colleague Katalin Kariko, developed the mRNA technology enabling the creation of the Covid-19 mRNA vaccines, to learn more about the science behind mRNA, the technology and his journey.

We discuss a male contraceptive study testing a gel as a possible new method for male family planning.

Acute respiratory distress syndrome (ARDS) is a very serious complication for many patients suffering from COVID-19, and is believed to account for about 80 percent of the deaths in ventilated patients.

The global crisis due to COVID19 and the urgent need to identify effective therapeutics prompted Dr. David Fajgenbaum from the University of Pennsylvania and his research team to create a database that tracks every off-label and experimental drug being used to treat COVID-19 patients.

Katharine Bar, MD discusses two studies that she is leading at Penn Medicine, using convalescent plasma therapy to treat severely and moderately ill COVID-19 patients.

We discuss Psoriasis treatment approaches with dermatologist Dr. Joel M. Gelfand.